N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

EV/EBIT
Enterprise Value to EBIT

0.9
Current
-9.2
Median
4.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
0.9
=
Enterprise Value
-568.5m NOK
/
EBIT
-58.9m USD
All Countries
Close
Market Cap EV/EBIT
NO
Nykode Therapeutics ASA
OSE:NYKD
918.2m NOK 0.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -215 658.5
US
Abbvie Inc
NYSE:ABBV
325.5B USD 24.4
US
Amgen Inc
NASDAQ:AMGN
150.4B USD 31.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD 26.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 10.2
US
Epizyme Inc
F:EPE
94.1B EUR -504.1
AU
CSL Ltd
ASX:CSL
135.7B AUD 25.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.7B USD 18.3
US
Seagen Inc
F:SGT
39.3B EUR -53.4
NL
argenx SE
XBRU:ARGX
34.6B EUR -76.9
EBIT Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBIT: 19.6
0.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 658.5 N/A
US
Abbvie Inc
NYSE:ABBV
24.4
88%
US
Amgen Inc
NASDAQ:AMGN
31.8
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504.1 N/A
AU
CSL Ltd
ASX:CSL
25.5
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.9 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
9.2
2-Years Forward
EV/EBIT
9.2
3-Years Forward
EV/EBIT
6.3

See Also

Discover More